$136.30
0.42% yesterday
Nasdaq, Oct 30, 09:00 pm CET
ISIN
IE00B4Q5ZN47
Symbol
JAZZ

Jazz Pharmaceuticals Plc Stock price

$136.30
+4.50 3.41% 1M
+19.34 16.54% 6M
+13.15 10.68% YTD
+23.12 20.43% 1Y
-7.49 5.21% 3Y
-7.80 5.41% 5Y
-0.98 0.71% 10Y
+118.57 668.75% 20Y
Nasdaq, Closing price Thu, Oct 30 2025
+0.57 0.42%

Key metrics

Basic
Market capitalization
$8.3b
Enterprise Value
$12.0b
Net debt
$3.7b
Cash
$1.7b
Shares outstanding
60.6m
Valuation (TTM | estimate)
P/E
negative | 25.4
P/S
2.0 | 1.9
EV/Sales
2.9 | 2.8
EV/FCF
9.6
P/B
2.2
Financial Health
Equity Ratio
34.1%
Return on Equity
13.7%
ROCE
6.9%
ROIC
5.3%
Debt/Equity
1.4
Financials (TTM | estimate)
Revenue
$4.1b | $4.3b
EBITDA
$1.2b | $797.0m
EBIT
$614.1m | $751.1m
Net Income
$-404.8m | $326.0m
Free Cash Flow
$1.2b
Growth (TTM | estimate)
Revenue
4.5% | 5.7%
EBITDA
1.1% | -41.1%
EBIT
-0.3% | 3.4%
Net Income
-202.5% | -41.8%
Free Cash Flow
22.0%
Margin (TTM | estimate)
Gross
88.7%
EBITDA
30.5% | 18.5%
EBIT
15.0%
Net
-9.9% | 7.6%
Free Cash Flow
30.3%
More
EPS
$-6.6
FCF per Share
$20.4
Short interest
8.9%
Employees
3k
Rev per Employee
$1.5m
Show more

Is Jazz Pharmaceuticals Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.

Jazz Pharmaceuticals Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

23x Buy
92%
2x Hold
8%

Analyst Opinions

25 Analysts have issued a Jazz Pharmaceuticals Plc forecast:

Buy
92%
Hold
8%

Financial data from Jazz Pharmaceuticals Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,087 4,087
5% 5%
100%
- Direct Costs 461 461
11% 11%
11%
3,625 3,625
4% 4%
89%
- Selling and Administrative Expenses 1,567 1,567
15% 15%
38%
- Research and Development Expense 811 811
9% 9%
20%
1,247 1,247
1% 1%
31%
- Depreciation and Amortization 633 633
3% 3%
15%
EBIT (Operating Income) EBIT 614 614
0% 0%
15%
Net Profit -405 -405
203% 203%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Jazz Pharmaceuticals Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jazz Pharmaceuticals Plc Stock News

Neutral
PRNewsWire
3 days ago
Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN , Oct. 28, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Ted W. Love, M.D.
Neutral
PRNewsWire
9 days ago
DUBLIN , Oct. 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 third quarter financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.
Neutral
Business Wire
10 days ago
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, announced it has entered into a research collaboration and drug supply agreement with Jazz Pharmaceuticals. Under the agreement, Jazz will provide zanidatamab (Ziihera®), a HER2-targeted bispecific antibody, at n...
More Jazz Pharmaceuticals Plc News

Company Profile

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Bruce Cozadd
Employees 2,800
Founded 2005
Website www.jazzpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today